Anidulafungin, a new antifungal drug

Antibiotiques

Volumn 9, Issue 3, 2007, Pages 212-215

  Bergogne Berezin E ^a  

^a NONE   (France)

Author keywords

Anidulafungin; Echinocandins; Invasive fungal infections

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ECHINOCANDIN; FLUCONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDIASIS; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SYNTHESIS; DRUG WITHDRAWAL; EXPERIMENTAL STUDY; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NEWBORN INFECTION; OUTCOME ASSESSMENT; PHARMACODYNAMICS; RADIATION DOSE FRACTIONATION; SPECIES INVASION; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 34948816609     PISSN: 12945501     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1294-5501(07)91381-3     Document Type: Article

References (7)

1. VASQUEZ JA. Treatment of candidiasis in hospitalized patients. Curr Treat Options in Infect Dis 2003 ; 11 : 495-506.
2. HABER J. Present situation and perspectives of antimycotics with systemic effect. Cas Lek Ces 2001 ; 140 : 596-604.
3. BRETAGNE S. Nouveaux antifongiques et nouvelles stratégies thérapeutiques dans les aspergilloses et candidoses invasives. Antibiotiques 2005 ; 7 : 5-15.
4. th ICAAC, Abstr M-1592.
5. DIEKEMA DJ, BOYKEN L, HOLLIS R, et al. Anidulafungin activity against invasive clinical isolates of Candida: relationship to fluconazole susceptibility. ICAAC 2006, Abstr M-362.
6. th ICAAC, Abstr A-1109.
7. Pfizer : AMM américaine pour Eraxis (™), Le Figaro, The financial Times - 23 février 2006, communiqué FDA.